Compare Rockwell Automation (ROK) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rockwell Automation vs Recursion Pharmaceuticals Inc — how do they compare? Rockwell Automation trades at $426.07 (market cap $47.65B), while Recursion Pharmaceuticals Inc trades at $3.23 (market cap $1.86B). The key difference: Rockwell Automation is far larger — about 25.6× Recursion Pharmaceuticals Inc's market cap, and Rockwell Automation pays a 1.29% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ROK | RXRX | |
|---|---|---|
Market Cap | $47.65B | $1.86B |
Sector | Industrials | Health |
52-Week High | $495.08 | $6.79 |
52-Week Low | $333.75 | $2.84 |
Enterprise Value | $50.79B | $1.38B |
Dividend Yield | 1.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rockwell Automation (ROK) trades at $429.13, down 1.08% on the day, with a bearish technical signal and near-term support at $427. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue for 2025 was $8.34B, with a net income margin of 13.38%, though profitability has moderated from 2023 peaks. Recent news highlights expansion in AI-driven quality systems and remote support capabilities.
The stock offers a 19.8% upside to the consensus price target of $514, supported by analyst optimism on margin expansion and reshoring trends. However, high valuation multiples (P/E 40.18) and mixed technical indicators suggest near-term volatility. Key risks include execution on growth initiatives and macroeconomic pressures on industrial spending.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rockwell Automation
Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.
Read more on ROK →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
